Related Experiment Videos
Deferred treatment in clinically localised prostatic carcinoma
J Adolfsson1, J Carstensen, T Löwhagen
1Department of Urology, Karolinska Hospital, Stockholm, Sweden.
British Journal of Urology
|February 1, 1992
Summary
Active surveillance for localized prostate cancer shows significant progression. Many patients experienced tumor advancement or metastasis, highlighting the need for careful monitoring in early-stage disease.
Area of Science:
- Oncology
- Urology
Background:
- Localized prostate cancer (T1-2) is often diagnosed cytologically.
- Active surveillance is a management option for early-stage prostate cancer.
Purpose of the Study:
- To evaluate the natural history of localized prostate cancer (T1-2) under active surveillance.
- To assess progression rates and mortality in patients with early-stage prostate carcinoma.
Main Methods:
- A cohort of 122 patients with localized prostate carcinoma (T1-2) was followed.
- No initial anti-tumour therapy was administered.
- Median follow-up duration was 91 months.
Main Results:
- 55% of patients experienced local tumor progression to stage T3.
- 14% developed distant metastases.
- 38% of patients died, with 7% attributed to prostate carcinoma.
Conclusions:
- Active surveillance in localized prostate cancer leads to significant progression.
- Long-term risks include local advancement, metastasis, and cancer-specific mortality.
- Careful monitoring is crucial for patients with early-stage prostate carcinoma.